首页> 美国卫生研究院文献>British Medical Journal >Effects of glucosamine chondroitin or placebo in patients with osteoarthritis of hip or knee: network meta-analysis
【2h】

Effects of glucosamine chondroitin or placebo in patients with osteoarthritis of hip or knee: network meta-analysis

机译:氨基葡萄糖软骨素或安慰剂对髋或膝骨关节炎患者的影响:网络荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective To determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee.>Design Network meta-analysis. Direct comparisons within trials were combined with indirect evidence from other trials by using a Bayesian model that allowed the synthesis of multiple time points. >Main outcome measure Pain intensity. Secondary outcome was change in minimal width of joint space. The minimal clinically important difference between preparations and placebo was prespecified at −0.9 cm on a 10 cm visual analogue scale.>Data sources Electronic databases and conference proceedings from inception to June 2009, expert contact, relevant websites.>Eligibility criteria for selecting studies Large scale randomised controlled trials in more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head.>Results 10 trials in 3803 patients were included. On a 10 cm visual analogue scale the overall difference in pain intensity compared with placebo was −0.4 cm (95% credible interval −0.7 to −0.1 cm) for glucosamine, −0.3 cm (−0.7 to 0.0 cm) for chondroitin, and −0.5 cm (−0.9 to 0.0 cm) for the combination. For none of the estimates did the 95% credible intervals cross the boundary of the minimal clinically important difference. Industry independent trials showed smaller effects than commercially funded trials (P=0.02 for interaction). The differences in changes in minimal width of joint space were all minute, with 95% credible intervals overlapping zero.>Conclusions Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space. Health authorities and health insurers should not cover the costs of these preparations, and new prescriptions to patients who have not received treatment should be discouraged.
机译:>目的,以确定氨基葡萄糖,软骨素或二者的组合对髋部或膝部骨关节炎的关节痛和疾病的放射学进展的影响。>设计网络元-分析。使用允许综合多个时间点的贝叶斯模型,将试验中的直接比较与其他试验的间接证据相结合。 >主要结局指标。次要结果是关节间隙最小宽度的改变。预先规定了制剂与安慰剂之间最小的临床重要差异,以10 cm的视觉模拟量表在-0.9 cm上进行。>数据来源电子数据库和会议记录,从成立到2009年6月,专家联系,相关网站。 strong>选择研究的资格标准针对200例膝关节或髋关节骨关节炎患者进行的大规模随机对照试验,比较了氨基葡萄糖,软骨素或其与安慰剂或头对头的组合。>结果 10个试验。在10 cm的视觉模拟量表上,与安慰剂相比,葡萄糖胺的总疼痛强度差异为-0.4 cm(95%可信区间-0.7至-0.1 cm),软骨素为-0.3 cm(-0.7至0.0 cm)和-组合时为0.5厘米(-0.9至0.0厘米)。没有一个估计值能使95%的可信区间跨过最小的临床重要差异的边界。独立于行业的试验显示的效果要小于商业资助的试验(相互作用的P = 0.02)。关节间隙最小宽度变化的差异都是微小的,95%的可信区间重叠为零。>结论C 与安慰剂,氨基葡萄糖,软骨素及其组合相比,并不能减轻关节疼痛或出现疼痛。对缩小关节间隙的影响。卫生当局和健康保险公司不应承担这些制剂的费用,并且不建议给未接受治疗的患者开新药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号